Celecoxib radiosensitizes the human cervical cancer HeLa cell line via a mechanism dependent on reduced cyclo-oxygenase-2 and vascular endothelial growth factor C expression

Journal of International Medical Research

Volumn 40, Issue 1, 2012, Pages 56-66

  Wang, A H ^a   Tian, Xiao Yu ^a   Yu, J J ^a   Mi, J Q ^a   Liu, H ^a   Wang, R F ^a  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Celecoxib; Cervical cancer; Cyclo oxygenase 2; Hela cells; Non steroidal anti inflammatory drugs; Radiosensitivity; Vascular endothelial growth factor C

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; VASCULOTROPIN C;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; GAMMA RADIATION; HELA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; RADIOSENSITIVITY; RADIOSENSITIZATION; UTERINE CERVIX CANCER;

EID: 84863289481     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001204000106     Document Type: Article

References (38)

1. Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Petignat P, Roy M: Diagnosis and management of cervical cancer. BMJ 2007; 335: 765-768.
3. Karar J, Maity A: Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol Ther 2009; 8: 1994-2001.
4. Cao Y, Prescott SM: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002; 190: 279-286.
5. Sahin M, Sahin E, Gümüslü S: Cyclooxygenase-2 in cancer and angiogenesis. Angiology 2009; 60: 242-253.
6. Terakado N, Shintani S, Yano J, et al: Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma. Oral Oncol 2004; 40: 383-389.
7. Bansal SS, Joshi A, Bansal AK: New dosage formulations for targeted delivery of cyclooxygenase-2 inhibitors: focus on use in the elderly. Drugs Aging 2007; 24: 441-451.
8. Chen KH, Hsu CC, Song WS, et al: Celecoxib enhances radiosensitivity in medulloblastomaderived CD133-positive cells. Childs Nerv Syst 2010; 26: 1605-1612.
9. Goldstein JL, Silverstein FE, Agrawal NM, et al: Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1681-1690.
10. Kishi K, Petersen S, Petersen C, et al: Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000; 60: 1326-1331.
11. Liu H, Xiao J, Yang Y, et al: COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer. J Microvasc Res 2011; 82: 131-140.
12. Spring E, Holmberg P: Evaluation of experimental irradiation fractionation with the single-hit, multi-target model. Acta Radiol Ther Phys Biol 1968; 7: 297-306.
13. Cheng AS, Chan HL, Leung WK, et al: Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. Mod Pathol 2004; 17: 1169-1179.
14. Chen YJ, Wang LS, Wang PH, et al: High cyclooxygenase-2 expression in cervical adenocarcinomas. Gynecol Oncol 2003; 88: 379-385.
15. + cells: improvement in radiotherapeutic effects. Laboratory investigation. J Neurosurg 2011; 114: 651-662.
16. Luo WR, Li LX, Li SY, et al: Influence of celecoxib on invasiveness of human highmetastatic nasopharyngeal carcinoma cell line CNE-2Z. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2010; 45: 941-945 [in Chinese, English abstract].
17. Milas L, Mason KA, Liao Z, et al: Chemoradiotherapy: emerging treatment improvement strategies. Head Neck 2003; 25: 152-167.
18. Koki AT, Leahy KM, Masferrer JL: Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Investig Drugs 1999; 8: 1623-1638.
19. 2 induces radioprotection in murine intestinal and hematopoietic stem cells. Radiat Res 1985; 103: 196-203.
20. de Rozenowicz R L, Santos RE, Silva MA, et al: Cox-2 and its association with prognostic factors and response to primary chemotherapy in patients with breast cancer. Rev Col Bras Cir 2010; 37: 323-327 [in English and Portuguese].
21. Wang M, He Y, Shi L, et al: Multivariate analysis by Cox proportional hazard model on prognosis of patient with epithelial ovarian cancer. Eur J Gynaecol Oncol 2011; 32: 171-177.
22. Mrena J, Wiksten JP, Kokkola A, et al: COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biol 2010; 31: 1-7.
23. Xia S, Zhao Y, Yu S, et al: Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells. Cancer Biother Radiopharm 2010; 25: 317-323.
24. Raju U, Nakata E, Yang P, et al: In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. Int J Radiat Oncol Biol Phys 2002; 54: 886-894.
25. Shah T, Ryu S, Lee HJ, et al: Pronounced radiosensitization of cultured human cancer cells by COX inhibitor under acidic microenvironment. Int J Radiat Oncol Biol Phys 2002; 53: 1314-1318.
26. Settakorn J, Khunamornpong S, Sukpan K, et al: Cyclooxygenase-2 expression in cervical squamous cell carcinoma: the significance of expression in neoplastic cells within the lymphovascular space. Asian Pac J Cancer Prev 2009; 10: 1011-1014.
27. Toomey DP, Murphy JF, Conlon KC: COX-2, VEGF and tumour angiogenesis. Surgeon 2009; 7: 174-180.
28. Kakiuchi Y, Tsuji S, Tsujii M, et al: Cyclooxygenase-2 activity altered the cellsurface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res 2002; 62: 1567-1572.
29. Steinauer KK, Gibbs I, Ning S, et al: Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. Int J Radiat Oncol Biol Phys 2000; 48: 325-328.
30. Patel ML, Subbaramaiah K, Du B, et al: Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005; 11: 1999-2007.
31. Kim SH, Song SH, Kim SG, et al: Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-iB as a possible target. J Cancer Res Clin Oncol 2004; 130: 551-560.
32. Raju U, Ariga H, Dittmann K, et al: Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib. Int J Radiat Oncol Biol Phys 2005; 63: 520-528.
33. Xu X, Yi F, Fu X, et al: Effects of celecoxib on the proliferation and apoptosis of human nasopharyngeal carcinoma cell line CNE-2. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2009; 23: 682-685 [in Chinese, English abstract].
34. Desai D, Kaushal N, Gandhi UH, et al: Synthesis and evaluation of the anti-inflammatory properties of selenium-derivatives of celecoxib. Chem Biol Interact 2010; 188: 446-456.
35. Mehar A, Macanas-Pirard P, Mizokami A, et al: The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents. J Pharmacol Exp Ther 2008; 324: 1181-1187.
36. von Rahden BH, Stein HJ, Pühringer F, et al: Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res 2005; 65: 5038-5044.
37. Kyzas, PA, Stefanou D, Agnantis NJ: COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma. Mod Pathol 2005; 18: 153-160.
38. Su JL, Shih JY, Yen ML, et al: Cyclooxygenase-2 induces EP1-and HER-2/Neu-dependent vascular endothelial growth factor-C upregulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res 2004; 64: 554-564.